Compare TPVG & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TPVG | NERV |
|---|---|---|
| Founded | 2013 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 224.9M | 210.1M |
| IPO Year | 2013 | 2014 |
| Metric | TPVG | NERV |
|---|---|---|
| Price | $4.48 | $4.11 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 2 |
| Target Price | $5.90 | ★ $10.50 |
| AVG Volume (30 Days) | 257.3K | ★ 358.2K |
| Earning Date | 05-06-2026 | 05-01-2026 |
| Dividend Yield | ★ 17.66% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | N/A | ★ $41,175,600.00 |
| Revenue This Year | $7.67 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.22 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.41 | $1.76 |
| 52 Week High | $7.24 | $12.46 |
| Indicator | TPVG | NERV |
|---|---|---|
| Relative Strength Index (RSI) | 37.96 | 40.62 |
| Support Level | N/A | $3.80 |
| Resistance Level | $5.70 | $4.59 |
| Average True Range (ATR) | 0.16 | 0.38 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 15.32 | 18.81 |
TriplePoint Venture Growth BDC Corp is a closed-end, non-diversified management investment company. Its investment objective is to maximize its total return to stockholders in the form of current income and, to a lesser extent, capital appreciation. The fund focuses on companies operating in the fields of biofuels, business applications software, wireless communications equipment, e-commerce, clothing and accessories, conferencing equipment and services, personal goods, financial institutions and services, entertainment, mixed retailing, and healthcare services. Geographically, all the firm's operations are located across the United States.
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.